Interesting, page-602

thinking in terms of news flow, we now have another field that can garnish market attention, re siemens.

Market awareness ? is about getting noticed. How many other journals will now pick up on the potential of the 20m mc junior, with IP being collaborated with a major ?

“We are very pleased to have Siemens Healthineers offer of assistance as we look at all the possibilities to
develop and commercialize our technology,” said Bob Proulx, Executive Chairman of Imagion Biosystems.
“The ability to use a targeted contrast agent like ours, in the MRI setting, could transform the way MRI is
used to diagnose cancer and other diseases. In entering into this collaboration, we will jointly gain insight
into the clinical and commercial potential of our novel technology. We are proud that Imagion continues to
attract the support of leading industry players and opinion leaders.”

“Siemens Healthineers has a strong focus on expanding Precision Medicine and transforming care delivery,”
said Dr Kieran O’Brien, Head of Collaborations and Research for Australia and New Zealand for Siemens
Healthcare Pty Ltd, “Imagion’s targeted contrast technology MagSense™ could offer patients a more
specific means to monitor cancer with MRI, and we look forward to assisting Imagion in investigating the
application of their technology with MRI scanners.”